Keyphrases
Add-on Therapy
12%
B Cells
62%
B Lymphocytes
100%
B-cell Depletion
12%
Beneficial Effects
12%
CCL19
12%
CD20
12%
Cellular Level
37%
Cellularity
12%
Central Nervous System
25%
Cerebrospinal Fluid
100%
Chemoattractant
12%
Chemokine Production
12%
Chemokines
100%
CXCL13
25%
Design Phase
12%
Enzyme-linked Immunosorbent Assay (ELISA)
12%
Flow Cytometry
12%
IgG Concentration
12%
IgG Index
12%
Immunomodulatory Drugs (IMiDs)
12%
Lumbar Puncture
12%
Magnetic Resonance Imaging
12%
Mean Reduction
12%
Mechanism of Action
12%
Monoclonal Antibody
12%
Multiple Sclerosis
100%
Oligoclonal Bands
12%
Phase II Trial
12%
Relapsing-remitting multiple Sclerosis
12%
Rituximab
87%
Rituximab Therapy
100%
T Cell Trafficking
12%
T Cells
100%
University of Washington
12%
Immunology and Microbiology
B Cell
100%
CCL19
12%
CD20
12%
Cell Level
37%
Cell Migration
12%
Central Nervous System
25%
Cerebrospinal Fluid
100%
Chemoattractant
12%
Chemokine
100%
CXCL13
25%
Enzyme-Linked Immunosorbent Assay
12%
Immunomodulatory Drug
12%
Magnetic Resonance Imaging
12%
Monoclonal Antibody
12%
Multiple Sclerosis
100%
Oligoclonal Band
12%
Relapsing Remitting Multiple Sclerosis
12%
Rituximab
100%
T Cell
100%
Neuroscience
B Cell
100%
CCL19
12%
CD20
12%
Cell Migration
12%
Central Nervous System
25%
Chemokine
100%
CXCL13
25%
Flow Cytometry
12%
Lumbar Puncture
12%
Magnetic Resonance Imaging
12%
Monoclonal Antibody
12%
Multiple Sclerosis
100%
Oligoclonal Band
12%
Relapsing Remitting Multiple Sclerosis
12%
Rituximab
100%
T Cell
100%